To the members of FIFA and the confederations

Circular no. 1567

Zurich, December 2016
ZBO/awe

WADA Prohibited List 2017 – comes into force January 2017

Dear Sir or Madam,

FIFA wishes to remind its member associations, the confederations, as well as all players, clubs and player support personnel that the World Anti-Doping Code Prohibited List 2017 and Methods issued by WADA will take effect on 1 January 2017. A summary of the modifications to the 2017 Prohibited List, including the 2017 Prohibited list is enclosed.

FIFA would like to remind all players that it is their duty to ensure that they do not take any forbidden substances and should inform themselves if in doubt regarding products and substances.

Thank you very much for your cooperation in this matter. Should you have any questions, please do not hesitate to contact FIFA's anti-doping unit at medical@fifa.org.

Yours faithfully,
FIFA

Zvonimir Boban
Deputy Secretary General (Football)

Encl.: - WADA Prohibited List 2017
- WADA summary of modifications 2017

Copies: - FIFA Council
- Medical Committee
- WADA
Prohibited Substances

S1 **ANABOLIC AGENTS**

- Compounds boldenone, boldione, 19-norandrostenedione, and nandrolone have been transferred and 19-norandrostenediol added to the S1.b section because they can be produced endogenously at low concentrations. This change does not affect the prohibited status of these substances. The interpretation and reporting of findings for these substances is addressed in specific Technical Documents [TD2016IRMS and/or TD2016NA].

- 5α-androst-2-ene-17-one, commonly known as “Delta-2” or 2-androstenone, was added as an example of metabolite of DHEA, more recently found in dietary supplements.

S2 **PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS**

- To extend the scope of Erythropoietic Stimulating Agents, GATA inhibitors (e.g. K-11706) and Transforming Growth Factor- β (TGF-β) inhibitors (e.g. sotatercept, luspatercept) were added.

- The International Nonproprietary Name (INN) of FG-4592, roxadustat, was added.

- Molidustat was added as another example of HIF stabilizer.

- Cobalt: It is re-iterated that vitamin B12, which contains cobalt, is not prohibited.

S3 **BETA-2-AGONISTS**

- The reference to isomers was simplified.

- Examples of selective and non-selective beta-2-agonists were added (fenoterol, formoterol, higenamine, indacaterol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, vilanterol).

- Higenamine is documented to be a constituent of the plant *Tinospora crispa*, which can be found in some dietary supplements and is a non-selective beta-2-agonist.

- Dosing parameters of salbutamol were refined to make it clear that the full 24 hour dose should not be administered at one time.

- The maximum dosage for salmeterol was stated according to the manufacturers’ recommendations.

- Studies are ongoing to establish an appropriate urinary threshold concentration for inhaled salmeterol. At present, the Technical Document TD2015MRPL recommends not to report salmeterol below 10 ng/mL.

S4 **HORMONE AND METABOLIC MODULATORS**

- Androsta-3,5-diene-7,17-dione (arimistane) was added as a new example of aromatase inhibitor.

Prohibited Methods

M1 **MANIPULATION OF BLOOD AND BLOOD COMPONENTS**

- Supplemental oxygen administered by inhalation, but not intravenously, is permitted. To clarify this, M1.2 now reads “excluding supplemental oxygen by inhalation.”
Substances and Methods
Prohibited In-Competition

STIMULANTS

- Lisdexamfetamine was added to S6.a; it is an inactive pro-drug of amphetamine.
- In the absence of an INN for methylhexaneamine, its International Union of Pure and Applied Chemistry (IUPAC) name, 4-methylhexan-2-amine, was added. A number of other synonyms exist for methylhexaneamine including: 1,3-dimethylamylamine, dimethylpentylamine; methylhexamine; methylhexanamine; 1,3-dimethylpentyamine.
- Regular food consumption will not yield sufficient levels of phenylethylamine to result in an Adverse Analytical Finding.

NARCOTICS

- Nicomorphine was added. It is an opioid analgesic drug, which is converted to morphine following administration.

GLUCOCORTICOIDS

- After consideration of stakeholders' comments, no changes were made in this section for 2017.

MONITORING PROGRAM

The following were added to establish patterns of use:

- Codeine;
- Concurrent use of multiple beta-2-agonists.
The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

This List shall come into effect on 1 January 2017
IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3.

PROHIBITED SUBSTANCES

S0 NON-APPROVED SUBSTANCES
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1 ANABOLIC AGENTS
Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)
a. Exogenous* AAS, including:

1-Androstenediol (5α-androst-1-ene-3β,17β-diol);
1-Androstenedione (5α-androst-1-ene-3,17-dione);
1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one);
4-Hydroxytestosterone (4,17β-dihydroxyandrostan-4-en-3-one);
Bolandiol (estr-4-ene-3β,17β-diol);
Bolasterone;
Calusterone;
Clostebol;
Danazol ([1,2]oxazolo[4′,5′:2,3]pregna-4-en-20-yn-17α-ol);
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one);
Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol);
Drostanolone;
Ethylestrenol (19-norpregna-4-en-17α-ol);
Fluoxymesterone;
Formebolone;
Furazabol (17α-methyl [1,2,5]oxadiazolo[3′,4′:2,3]-5α-androstan-17β-ol);
Gestrinone;

Mestanolone;
Mesterolone;
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one);
Metenolone;
Methandriol;
Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one);
Methyl-dienolone (17β-hydroxy-17α-methylene-4,9-dien-3-one);
Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one);
Methyl-nortestosterone (17β-hydroxy-17α-methylene-4-en-3-one);
Methyltestosterone;
Metribolone (methyltrienolone, 17β-hydroxy-17α-methylene-4,9,11-trien-3-one);
Mibolerone;
Norboletone;
Norclostebol;
Norethandrolone;
Oxabolone;
Oxandrolone;
Oxymesterone;
Oxymetholone;
Prostanzolol [17β-[[tetrahydropyran-2-yl]oxy]-1'H-pyrrozolo[3,4,2,3]-5α-androstan-17β-ol];
Quinbolone;
Stanzolol;
Stenbolone;
Tetrahydrogestrinone (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-one);
Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);

and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous** AAS when administered exogenously:

- **Norandrostenediol (estr-4-ene-3,17-diol);**
- **Norandrostenedione (estr-4-ene-3,17-dione);**
- **Androstenediol (androst-5-ene-3β,17β-diol);**
- **Androstenedione (androst-4-ene-3,17-dione);**
- **Boldenone;**
- **Boldione (androsta-1,4-diene-3,17-dione);**
- **Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one);**
- **Nandrolone (19-nortestosterone);**
- **Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one);**
- **Testosterone;**

and their metabolites and isomers, including but not limited to:

- **3β-Hydroxy-5α-androstan-17-one;**
- **5α-Androst-2-ene-17-one;**
- **5α-Androstane-3α,17α-diol;**
- **5α-Androstane-3α,17β-diol;**
- **5α-Androstane-3β,17α-diol;**
- **5α-Androstane-3β,17β-diol;**
- **5β-Androstane-3α,17β-diol;**
- **7α-Hydroxy-DHEA;**
- **7β-Hydroxy-DHEA;**
- **4-Androstenediol (androst-4-ene-3β, 17β-diol);**
- **5-Androstenedione (androst-5-ene-3,17-dione);**
- **7-Keto-DHEA;**
- **Norandrosterone;**
- **Noretioclanolone;**
- **Androst-4-ene-3α,17α-diol;**
- **Androst-4-ene-3α,17β-diol;**
- **Androst-4-ene-3β,17α-diol;**
- **Androst-5-ene-3α,17α-diol;**
- **Androst-5-ene-3α,17β-diol;**
- **Androst-5-ene-3β,17α-diol;**
- **Androsterone;**
- **Epi-dihydrotestosterone;**
- **Epitestosterone;**
- **Etioclanolone.**

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

- Clenbuterol;
- Selective androgen receptor modulators (SARMs, e.g. andarine and ostarine);
- Tibolone;
- Zeranol;
- Zilpaterol.

**For purposes of this section:**

- "exogenous" refers to a substance which is not ordinarily produced by the body naturally.
- **endogenous** refers to a substance which is ordinarily produced by the body naturally.

S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. Erythropoietin-Receptor agonists:
   1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; GATA inhibitors, e.g. K-11706; Methoxy polyethylene glycol-epoetin beta (CERA); Transforming Growth Factor-β (TGF-β) inhibitors, e.g. sotatercept, luspatercept;

1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290; Asialo EPO; Carbamylated EPO.

2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt, moldidustat and roxadustat (FG-4592); and HIF activators, e.g. argon and xenon.
3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and leuprorelin, in males.

4. Corticotrophins and their releasing factors, e.g. corticorelin.

5. Growth Hormone (GH) and its releasing factors including:
   - Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin;
   - Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin;
   - GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin, and pralmorelin (GHRP-2).

Additional prohibited growth factors:

- Fibroblast Growth Factors (FGFs);
- Hepatocyte Growth Factor (HGF);
- Insulin-like Growth Factor-1 (IGF-1) and its analogues;
- Mechano Growth Factors (MGFs);
- Platelet-Derived Growth Factor (PDGF);
- Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity, or fibre type switching.

**BETA-2 AGONISTS**

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.

Including, but not limited to:
- Fenoterol;
- Formoterol;
- Higenamine;
- Indacaterol;
- Olodaterol;
- Procarderol;
- Reproterol;
- Salbutamol;
- Salmeterol;
- Terbutaline;
- Vilanterol.

**Except:**

- Inhaled salbutamol: maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours;
- Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic dose (by inhalation) up to the maximum dose indicated above.

**HORMONE AND METABOLIC MODULATORS**

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to:
   - 4-Androstene-3,6,17-trione (6-oxo);
   - Aminoglutethimide;
   - Anastrozole;
   - Androsta-1,4,6-triene-3,17-dione (androstatrienedione);
   - Androsta-1,4,6,9-tetraene-3,17-dione (androstatrienedione);
   - Exemestane;
   - Formestane;
   - Letrozole;
   - Testolactone.

2. Selective estrogen receptor modulators (SERMs) including, but not limited to:
   -Raloxifene;
   -Tamoxifen;
   -Toremifene.

3. Other anti-estrogenic substances including, but not limited to:
   -Clomiphene;
   -Cyclofenil;
   -Fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors.

5. Metabolic modulators:
   5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516;
   5.2 Insulins and insulin-mimetics;
   5.3 Meldonium;
   5.4 Trimetazidine.

DIURETICS AND MASKING AGENTS
The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:
- Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol;
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.

Except:
- Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);
- Local administration of felypressin in dental anaesthesia.

The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

PROHIBITED METHODS

MANIPULATION OF BLOOD AND BLOOD COMPONENTS
The following are prohibited:
1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

2. Artificially enhancing the uptake, transport or delivery of oxygen.
   Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

CHEMICAL AND PHYSICAL MANIPULATION
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.
   Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases.

2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

GENE DOPING
The following, with the potential to enhance sport performance, are prohibited:
1. The transfer of polymers of nucleic acids or nucleic acid analogues.

2. The use of normal or genetically modified cells.
IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION:

PROHIBITED SUBSTANCES

---

**STIMULANTS**

All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

**a: Non-Specified Stimulants:**

- Adrafinil;
- Amfepramone;
- Amfetamine;
- Amfetaminal;
- Amphenazone;
- Benfluorex;
- Benzylpiperazine;
- Bromantan;
- Clobenzorex;
- Cocaine;
- Cropropamide;
- Crotetamide;
- Fenflamine;
- Fenfluoxetine;
- Fenfluramine;
- Fenproporex;
- Fonturacetam [4-phenylpiracetam {carphedon}];
- Furfenorex;
- Lisdexamfetamine;
- Mefenorex;
- Mephentermine;
- Mesocarb;
- Metamfetamine{d-};
- p-methylamphetamine;
- Modafinil;
- Norfenfluramine;
- Phendimetrazine;
- Phentermine;
- Prenylamine;
- Prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

**b: Specified Stimulants.**

Including, but not limited to:

- 4-Methylhexan-2-amine (methylhexaneamine);
- Benzetamine;
- Cathine**;
- Cathinone and its analogues, e.g. mephedrone, methedrone, and a-pyrrolidinovalerophenone;
- Dimethylamphetamine;
- Ephedrine***;
- Epinephrine**** (adrenaline);
- Etamivan;
- Etilamfetamine;
- Etilefrine;
- Famprofazone;
- Fenbutrazate;
- Fencamfamin;
- Heptaminol;
- Hydroxyamfetamine [parahydroxyamphetamine];
- Isometheptene;
- Levmetamfetamine;
- Meclofenoxate;
- Methylenedioxymethamphetamine;
- Methylephedrine***;
- Methylphenidate;
- Nikethamide;
- Norfenefrine;
- Octopamine;
- Oxilofrine [methylsympathine];
- Pemoline;
- Pentetrazol;
- Phenethyamine and its derivatives;
- Phenmetrazine;
- Phenpromethamine;
- Propylhexedrine;
- Pseudoephedrine*****;
Selegiline; Sibutramine; Strychnine; 
Tetramfetamine [methyleneoxyamphetamine]; Tuaminoheptane;

and other substances with a similar chemical structure or similar biological effect(s).

Except:
• Clonidine;
• Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2017 Monitoring Program*.

* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2017 Monitoring Program, and are not considered Prohibited Substances.

** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

---

**NARCOTICS**

Prohibited:
- Buprenorphine;
- Dextromoramide;
- Diamorphine (heroin);
- Fentanyl and its derivatives;
- Hydromorphone;
- Methadone;
- Morphine;
- Nicomorphine;
- Oxycodone;
- Oxymorphone;
- Pentazocine;
- Pethidine.

---

**CANNABINOIDS**

Prohibited:
• Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC).

---

**GLUCOCORTICOIDS**

All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular, or rectal routes.
**P1** ALCOHOL
Alcohol (ethanol) is prohibited *In-Competition only,* in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.
- Air Sports (FAI)
- Archery (WA)
- Automobile (FIA)
- Powerboating (UIM)

**P2** BETA-BLOCKERS
Beta-blockers are prohibited *In-Competition only,* in the following sports, and also prohibited *Out-of-Competition* where indicated.
- Archery (WA)*
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Shooting (ISSF, IPC)*
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea.

*Also prohibited *Out-of-Competition*

Including, but not limited to:

- Acebutolol
- Alpenolol
- Atenolol
- Betaxolol
- Bisoprolol
- Bunolol
- Carteolol
- Carvedilol
- Celiprolol
- Esmolol
- Labetalol
- Levobunolol
- Metipranolol
- Metoprolol
- Nadolol
- Oxprenolol
- Pindolol
- Propranolol
- Sotalol
- Timolol.